Write your message
Iranian Journal of Breast Diseases                   Back to the articles list | Back to browse issues page

XML Persian Abstract Print


1- Department of Biology, Ard.C., Islamic Azad University, Ardabil, Iran , yaghoubi_h@iau.ac.ir
2- Traditional Medicine and Hydrotherapy Research Center, Ardabil University Of Medical Sciences, Ardabil, Iran
Abstract:   (18 Views)

Introduction: Nanotechnology addresses the challenge of targeted delivery of drugs and nucleic acids to cancer cells by designing smart delivery systems. This approach enables improved precision and efficiency in the delivery of therapeutic agents. This study focuses on the design and evaluation of a folic acid (FA)-functionalized, PLA/Chitosan/PEG-based multifunctional nanocarrier with tumor-targeting capability and synergistic co-delivery of paclitaxel (PTX) and siRNA to breast cancer cells (MCF-7), aiming to enhance selective uptake and therapeutic efficiency compared to conventional delivery systems.
Methods: PCPF nanoparticles were synthesized and co-loaded with PTX and Survivin-targeting siRNA. FTIR and DLS characterized physicochemical properties. Cargo release was evaluated at different pH values, while cytotoxicity and apoptosis were assessed in MCF-7 and MCF-10A cells using MTT and Annexin V/PI assays, respectively.
Results: FTIR confirmed successful PCPF nanoparticle synthesis. Particle size increased from 162 ± 6 nm to 256 ± 11 nm after PTX/siRNA loading, while zeta potential remained mainly negative. Nanocapsules exhibited pH-responsive sustained release, with greater cargo release at pH 5.0. Cytotoxicity studies demonstrated enhanced selectivity for MCF-7 cells, with PCPF/PTX/siRNA inducing the highest apoptosis, whereas free PTX caused the greatest necrosis.
Conclusion: Folic acid-targeted PCPF nanoparticles enhanced PTX/siRNA co-delivery, promoting selective cytotoxicity, apoptosis, and improved anticancer efficacy.

Full-Text [PDF 5079 kb]   (5 Downloads)    
Type of Study: Research | Subject: molecular cell
Received: 2025/11/8 | Accepted: 2026/06/3

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2026 CC BY-NC 4.0 | Iranian Journal of Breast Diseases

Designed & Developed by: Yektaweb